Thyroid Gland: Drugs

Department of Health and Social Care written question – answered on 25th January 2018.

Alert me about debates like this

Photo of Richard Burden Richard Burden Labour, Birmingham, Northfield

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that medicines approved for patients with thyroid conditions are competitively priced.

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary for Health and Social Care

The costs of branded medicine are controlled by the Pharmaceutical Price Regulation Scheme and the statutory scheme for branded medicines. For unbranded generic medicines, the Department encourages competition between suppliers to keep prices down. In primary care, community pharmacies are incentivised to source products at the lowest possible cost and in secondary care, competitive tenders ensure value-for-money to the National Health Service.

Where competition does not appear to be working, the Department alerts the Competition and Markets Authority (CMA). Where the CMA finds that a company has breached competition law by charging excessive prices, it can impose a fine as well as order companies to reduce their prices. In those instances the Department can and does seek damages and invests that money back into the NHS.

Does this answer the above question?

Yes0 people think so

No1 person thinks not

Would you like to ask a question like this yourself? Use our Freedom of Information site.